LEXEO Therapeutics utilizes gene therapy to treat genetically defined cardiovascular and central nervous system diseases.
LEXEO Therapeutics has raised $154.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2025.
LEXEO Therapeutics's investors include RA Capital Management, Janus Henderson Investors, Balyasny Asset Management, Novo Holdings, Invus.
LEXEO Therapeutics is headquartered in New York, United States.
LEXEO Therapeutics utilizes gene therapy to treat genetically defined cardiovascular and central nervous system diseases.
LEXEO Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"LEXEO Therapeutics — Funding & Investors." VCBacked, October 16, 2025, https://www.vcbacked.co/company/lexeo-therapeutics. Accessed August 8, 2026.
VCBacked. (2025). LEXEO Therapeutics — Funding & Investors. Retrieved August 8, 2026, from https://www.vcbacked.co/company/lexeo-therapeutics
{{cite web |title=LEXEO Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/lexeo-therapeutics |website=VCBacked |access-date=August 8, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated